Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Novartis Pharmaceuticals
The Primary objective of the study was to evaluate the overall clinical benefit response (CBR) rate. This was a single arm, open-label, multi-center study of lapatinib plus capecitabine in women from mainland China and Hong Kong who had advanced or metastatic breast cancer that progressed on prior chemotherapies with or without trastuzumab. Participants received study treatment until disease progression, unacceptable toxicity, or withdrawal for any other reasons.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted